Related Experiment Videos
Comparative in vitro activity of furopenem against aerobic bacteria isolated from pediatric patients
1Department of Laboratories, St. Christopher's Hospital for Children, Philadelphia, Pennsylvania 19134, USA.
Abstract:
The in vitro activity of the oral penem furopenem (WY-49605, 545555, SUN5555, and ALP201) was tested against clinical bacteria isolated from pediatric patients. Furopenem was compared with clarithromycin, cefpodoxime, amoxicillin, amoxicillin-clavulanate, cefaclor, cefixime, and cefuroxime. Furopenem demonstrated consistent activity against Escherichia coli [minimum inhibitory concentration (MIC90) = 1.0 microgram/ml)] Klebsiella pneumoniae (MIC90 = 2.0 micrograms/ml), Salmonella enteriditis and Shigella spp. (MIC90 = 1.0 microgram/ml), and beta-lactamase-positive or -negative Haemophilus influenzae (MIC90 = 1.0 microgram/ml) and Moraella catarrhalis (MIC90 = 1.0 microgram/ml). Furopenem was also active against a number of the Gram-positive organisms tested including methicillin-susceptible Staphylococcus aureus and penicillin-susceptible Streptococcus pneumoniae. These results suggest a potential application for this agent in the treatment of children as outpatients.
Insights
The oral antibiotic furopenem shows strong in vitro activity against common pediatric bacterial infections, including E. coli and H. influenzae. This suggests furopenem
Area of Science:
- Microbiology
- Pharmacology
- Pediatric Infectious Diseases
Background:
- Antibiotic resistance is a growing concern in pediatric infectious diseases.
- Novel antimicrobial agents are needed to combat resistant bacterial strains.
- Furopenem is an oral penem antibiotic with potential for outpatient use.
Purpose of the Study:
- To evaluate the in vitro antibacterial activity of furopenem.
- To compare furopenem's efficacy against common pediatric pathogens with existing antibiotics.
- To assess furopenem's potential as an outpatient treatment for children.
Main Methods:
- In vitro susceptibility testing of furopenem against clinical bacterial isolates from pediatric patients.
- Determination of minimum inhibitory concentrations (MIC90) for key bacterial species.
- Comparative analysis of furopenem activity against clarithromycin, cefpodoxime, and other relevant antibiotics.
Main Results:
- Furopenem demonstrated potent activity against Gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniae, Salmonella enteriditis, Shigella spp., Haemophilus influenzae, and Moraxella catarrhalis.
- MIC90 values for furopenem against these Gram-negative pathogens ranged from 1.0 to 2.0 micrograms/ml.
- The agent also showed activity against methicillin-susceptible Staphylococcus aureus and penicillin-susceptible Streptococcus pneumoniae.
Conclusions:
- Furopenem exhibits broad-spectrum in vitro activity against clinically relevant bacteria found in pediatric infections.
- Its consistent efficacy against key pathogens suggests a promising role for furopenem in pediatric outpatient therapy.
- Further clinical investigation is warranted to confirm furopenem's therapeutic potential in children.